The purpose of this article is to review the treatment of a patient with type 2 diabetes who is commonly seen in practice—specifically, a middle-aged obese patient with micro- and macrovascular complications whose A1C rises after therapeutic intervention. Discussion of glucose management, as well as hypertension, dyslipidemia, and obesity comorbidities, is included.
Conclusion
The key to successful treatment is individualization of targets and therapeutic choices. GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes, including aiding with A1C reduction and weight loss. Using a combination of old and new treatments for the management of diabetes can help to improve outcomes.
Get full access to this article
View all access options for this article.
References
1.
BarkerLEKirtlandKAGreggEWGeissLSThompsonTJ. Geographic distribution of diagnosed diabetes in the US. A diabetes belt. Am J Prev Med. 2011;40:434-439.
2.
McWilliamsJMMearaEZaslavskyAMAyanianJZ. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: U.S. trends from 1999 to 2006 and effects of medicare coverage. Ann Intern Med. 2009;150:505-515.
3.
ChaturvediN. The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract. 2007;76(suppl 1):S3-S12.
4.
GaedePVedelPLarsenN. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
5.
SpannSJNuttingPAGalliherJM. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med. 2006;4(1):23-31.
6.
ChenJAlemaoEYinDCookJ. Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications. Diabetes Obes Metab. 2008;10(suppl 1):33-42.
7.
RochesterCDLeonNDombrowskiRHainesST. Collaborative drug therapy management for initiating and adjusting insulin therapy in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2010;67(1):42-48.
8.
van BruggenRGorterKStolkR. Clinical inertia in general practice: widespread and related to the outcome of diabetes care. Fam Pract. 2009;26(6):428-436.
9.
BolenSDBrickerESamuelsTA. Factors associated with intensification of oral diabetes medications in primary care provider-patient dyads: a cohort study. Diabetes Care. 2009;32(1):25-31.
10.
Ismail-BeigiFMoghissiETiktinM. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154(8):554-559.
11.
GaedePLund-AndersenHParvingHHPedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
12.
SkylerJSBergenstalRBonowRO. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53(3):298-304.
13.
ZoungasSPatelAChalmersJ. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410-1418.
14.
UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
15.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(140):977-986.
16.
OhkuboYKishikawaHArakiE. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.
17.
UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
18.
StrattonIMAdlerAINeilHA. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
19.
HolmanRRPaulSKBethelMA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
20.
DuckworthWAbrairaCMoritzT. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
21.
NathanDMClearyPABacklundJY. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653.
22.
CornellS. Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach. J Clin Pharm Ther. 2012;37(3):254-259.
23.
NathanDMBuseJBDavidsonMB. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
24.
RodbardHWJellingerPSDavidsonJA. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
25.
MonamiMCremascoFLamannaC. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362-372
26.
MonnierLLapinskiHColetteC. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881-885.
27.
PratleyRENauckMBaileyT. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456.
28.
WyshamCBergenstalRMalloyJ. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabetic Med. 2011;28(6):705-714.
29.
BuseJBRosenstockJSestiG. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
30.
BlevinsTPullmanJMalloyJ. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrin Metab. 2011;96(5):1301-1310.
31.
ZinmanBSchmidtWEMosesA. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab. 2012;14(1):77-82.
32.
KlonoffDCBuseJBNielsenLL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-286.
33.
GarberAHenryRRRatnerR. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348-356.
34.
RaschiEPiccinniCPoluzziE. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database [published online ahead of print October 9, 2011]. Acta Diabetol.
35.
ParksMRosebraughC. Weighing risks and benefits of liraglutide: the FDA’s review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774-777.
von GoelerDSRosalMCOckeneJK. Self-management of type 2 diabetes: a survey of low-income urban Puerto Ricans. Diabetes Educ. 2003;29(4):663-672.
38.
RheeMKCookCBEl-KebbiI. Barriers to diabetes education in urban patients: perceptions, patterns, and associated factors. Diabetes Educ. 2005;31(3):410-417.
39.
SchillingerDPietteJGrumbachK. Closing the loop: physician communication with diabetic patients who have low health literacy. Arch Int Med. 2003;163(1):83-90.
40.
KountzDS. Strategies for improving low health literacy. Postgrad Med. 2009;121(5):171-177.
41.
ClancyDEYeagerDEHuangPMagruderKM. Further evaluating the acceptability of group visits in an uninsured or inadequately insured patient population with uncontrolled type 2 diabetes. Diabetes Educ. 2007;33(2):309-314.
42.
TangTSFunnellMMNoorullaS. Sustaining short-term improvements over the long-term: results from a 2-year diabetes self-management support (DSMS) intervention. Diabetes Res Clin Pract. 2012;95(1):85-92.
43.
Rahim-WilliamsB. Beliefs, behaviors, and modifications of type 2 diabetes self-management among African American women. J Natl Med Assoc. 2011;103(3):203-215.
44.
WingRR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-1575.
45.
CampbellIW. Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?Int J Clin Pract. 2010;64(6):791-801.
46.
MeneghiniLFOrozco-BeltranDKhuntiK. Weight beneficial treatments for type 2 diabetes. J Clin Endocrin Metab. 2011;96(11):3337-3353.
47.
VilsbollTZdravkovicMLe-ThiT. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608-1610.
48.
JendleJNauckMAMatthewsDR. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163-1172.
49.
Abu-HamdahRRabieeAMeneillyGS. Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrin Metab. 2009;94(6):1843-1852.
50.
DavidsonMH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011;108(3)(suppl):33B-41B.
51.
FonsecaVA. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol. 2011;108(3)(suppl):52B-58B.
52.
PeskinBRShcheprovAVBoyeKS. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs traditional therapies for type 2 diabetes: a simulation analysis. Diabetes Obes Metab. 2011;13(10):921-927.
53.
MonamiMCremascoFLamannaC. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011:215764.
54.
RatnerRHanJNicewarnerD. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
55.
CourrègesJPVilsbøllTZdravkovicM. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med. 2008;25(9):1129-1131.
56.
MarsoSPLindseyJBStolkerJM. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8(3):237-240.
57.
VaranasiAPatelPMakdissiA. Clinical use of liraglutide in type 2 diabetes, and its effects on cardiovascular risk factors. Endocr Pract. 2011;19:1-13.
58.
MageeMBowlingACopelandJ. The ABCs of diabetes: diabetes self-management education program for African Americans affects A1C, lipid-lowering agent prescriptions, and emergency department visits. Diabetes Educ. 2011;37(1):95-103.
59.
BoltriJMDavis-SmithMOkosunIS. Translation of the National Institutes of Health Diabetes Prevention Program in African American churches. J Natl Med Assoc. 2011;103(3):194-202.
60.
DodaniSFieldsJZ. Implementation of the fit body and soul, a church-based life style program for diabetes prevention in high-risk African Americans: a feasibility study. Diabetes Educ. 2010;36(3):465-72.
61.
BaigAAWilkesAEDavisAM. The use of quality improvement and health information technology approaches to improve diabetes outcomes in African American and Hispanic patients. Med Care Res Rev. 2010;67:163S-97S.
